Company intelligence / Profile preview

DelArrivo, Inc.

Morrisville, North Carolina, United Statessosnc.gov ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

DelArrivo, Inc. is a private pharmaceutical company focused on developing treatments for dermatological conditions. Its lead asset, DLX105-DMP, has completed a Phase 1 clinical trial investigating safety and preliminary efficacy in mild-to-moderate plaque psoriasis. The study was an open-label pilot evaluating dosing feasibility and tolerability over four weeks; results are not publicly detailed but the program remains active as of early 2025[1].

Therapeutic areas: Dermatology
Modalities: Not explicitly stated; likely small molecules or topical formulations (based on the context of a psoriasis drug candidate)
Industry: Biotech

Partnerships

No major partnerships disclosed in public sources as of May 2025.

Beyond the preview

Go deeper on DelArrivo, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DelArrivo, Inc..

Explore the full profile